← Back to Search

Aminoglycoside Antibiotic

Gentamicin Sulfate for Epidermolysis Bullosa

Phase 1 & 2
Recruiting
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. JEB patients with nonsense mutations in the LAMB3 gene in either one or two alleles.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will test if gentamicin can be used to treat Herlitz junctional epidermolysis bullosa (H-JEB), an incurable skin disease, by restoring laminin 332 assembly and improving wound closure.

Eligible Conditions
  • Epidermolysis Bullosa

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Generation of new hemidesmosomes as assessed by electron microscopy.
Incidence of Treatment-Emergent Adverse Events
Increased laminin beta 3 / laminin 332 expression as assessed by immunofluorescence.
Secondary outcome measures
Improved wound closure.
Reduction in blistering

Trial Design

1Treatment groups
Experimental Treatment
Group I: Gentamicin SulfateExperimental Treatment1 Intervention
IV Arm: 7.5 mg/kg gentamicin once daily for 14 days. Topical Arm: 0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gentamicin
FDA approved

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
905 Previous Clinical Trials
1,596,272 Total Patients Enrolled
4 Trials studying Epidermolysis Bullosa
26 Patients Enrolled for Epidermolysis Bullosa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Gentamicin for Junctional Epidermolysis Bullosa
David Woodley 2018. "Gentamicin for Junctional Epidermolysis Bullosa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03526159.
All > Epidermolysis Bullosa
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top